(Q37109589)

English

Evaluation of the pharmacokinetic effects of various linking group using the 111In-DOTA-X-BBN(7-14)NH2 structural paradigm in a prostate cancer model

scientific article published on 20 August 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Evaluation of the pharmacokinetic effects of various linking group using the 111In-DOTA-X-BBN(7-14)NH2 structural paradigm in a prostate cancer model (English)

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

prostate cancer

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

Jered C Garrison

1

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Tammy L Rold

2

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Gary L Sieckman

3

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Farah Naz

4

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Samantha V Sublett

5

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Said Daibes Figueroa

6

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Wynn A Volkert

7

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Timothy J Hoffman

8

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

20 August 2008

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Bioconjugate Chemistry

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

19

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

9

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

1803-1812

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2647743

14 September 2017

[64Cu-NOTA-8-Aoc-BBN(7-14)NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2647743

14 September 2017

Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2647743

14 September 2017

Evaluation of combined (177)Lu-DOTA-8-AOC-BBN (7-14)NH(2) GRP receptor-targeted radiotherapy and chemotherapy in PC-3 human prostate tumor cell xenografted SCID mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2647743

14 September 2017

Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2647743

14 September 2017

Renal toxicity after radionuclide therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2647743

14 September 2017

Gastrin releasing peptide (GRP) receptor targeted radiopharmaceuticals: a concise update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2647743

14 September 2017

Monoclonal antibody drug immunoconjugates for targeted treatment of cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2647743

14 September 2017

Therapeutic radiopharmaceuticals

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2647743

14 September 2017

Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2647743

14 September 2017

In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2647743

29 September 2017

DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2647743

29 September 2017

177Lu-AMBA: Synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2647743

29 September 2017

18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2647743

29 September 2017

Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2647743

27 June 2018

Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2647743

27 June 2018

The effects of linking substituents on the in vivo behavior of site-directed, peptide-based, diagnostic radiopharmaceuticals.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2647743

3 September 2018

Selective in vitro targeting of GRP and NMB receptors in human tumours with the new bombesin tracer 177Lu-AMBA.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2647743

3 September 2018

Preparation of cyclotron-produced 186Re and comparison with reactor-produced 186Re and generator-produced 188Re for the labeling of bombesin.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2647743

3 September 2018

Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2647743

3 September 2018

Radiochemical investigations of (99m)Tc-N(3)S-X-BBN[7-14]NH(2): an in vitro/in vivo structure-activity relationship study where X = 0-, 3-, 5-, 8-, and 11-carbon tethering moieties

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2647743

3 September 2018

Pm-149 DOTA bombesin analogs for potential radiotherapy. in vivo comparison with Sm-153 and Lu-177 labeled DO3A-amide-betaAla-BBN(7-14)NH(2).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2647743

3 September 2018

Novel series of 111In-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/18712899

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Species differences of bombesin analog interactions with GRP-R define the choice of animal models in the development of GRP-R-targeting drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/18712899

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Synthesis, biodistribution and renal handling of various chelate-somatostatin conjugates with metabolizable linking groups

1 reference

https://pubmed.ncbi.nlm.nih.gov/18712899

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radiochemical investigations of 177Lu-DOTA-8-Aoc-BBN[7-14]NH2: an in vitro/in vivo assessment of the targeting ability of this new radiopharmaceutical for PC-3 human prostate cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/18712899

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radiometal-labeled agents (non-technetium) for diagnostic imaging

1 reference

https://pubmed.ncbi.nlm.nih.gov/18712899

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bombesin receptor subtypes in human cancers: detection with the universal radioligand (125)I-[D-TYR(6), beta-ALA(11), PHE(13), NLE(14)] bombesin(6-14)

1 reference

https://pubmed.ncbi.nlm.nih.gov/18712899

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1021/BC8001375

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37109589&oldid=2143313056"